These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23973321)

  • 21. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
    Paradiso PR
    Clin Infect Dis; 2011 May; 52(10):1241-7. PubMed ID: 21507921
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine.
    Frenck R; Thompson A; Senders S; Harris-Ford L; Sperling M; Patterson S; Devlin C; Jansen KU; Gruber WC; Emini EA; Scott DA; Gurtman A
    Pediatr Infect Dis J; 2014 Feb; 33(2):183-9. PubMed ID: 24136369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.
    Chevallier B; Vesikari T; Brzostek J; Knuf M; Bermal N; Aristegui J; Borys D; Cleerbout J; Lommel P; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S109-18. PubMed ID: 19325447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan.
    Huang LM; Lin TY; Juergens C
    Vaccine; 2012 Mar; 30(12):2054-9. PubMed ID: 22198517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(9):258-61. PubMed ID: 20224542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody responses to routine pediatric vaccines administered with 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Gurtman A; Girgenti D; Reisinger K; Johnson A; Pride MW; Patterson S; Devlin C; Gruber WC; Emini EA; Scott DA
    Pediatr Infect Dis J; 2013 Apr; 32(4):383-8. PubMed ID: 23104129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants.
    Olivier C; Belohradsky BH; Stojanov S; Bonnet E; Petersen G; Liese JG
    Vaccine; 2008 Jun; 26(25):3142-52. PubMed ID: 18502545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 13-valent pneumococcal conjugate vaccine.
    Prescrire Int; 2011 Jan; 20(112):5-7, 9. PubMed ID: 21462782
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly.
    Durando P; Rosselli R; Cremonesi I; Orsi A; Albanese E; Barberis I; Paganino C; Trucchi C; Martini M; Marensi L; Turello V; Study Group TL; Bregante A; Cacciani R; Iudici R; La Marca D; Pedano L; Petrucci AF; Santolini M; Sbisà V; Zacconi M
    Hum Vaccin Immunother; 2015; 11(1):172-7. PubMed ID: 25483531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity, safety and tolerability of 3 lots of 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in the United States.
    Payton T; Girgenti D; Frenck RW; Patterson S; Love J; Razmpour A; Sidhu MS; Emini EA; Gruber WC; Scott DA
    Pediatr Infect Dis J; 2013 Aug; 32(8):871-80. PubMed ID: 23584582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of a multidose vial formulation of 13-valent pneumococcal conjugate vaccine administered with routine pediatric vaccines in healthy infants in India: A phase 4, randomized, open-label study.
    Lalwani SK; Ramanan PV; Sapru A; Sundaram B; Shah BH; Kaul D; Karthik Nagesh N; Kalina WV; Chand R; Ding M; Suroju S; Scott DA; Lockhart SP
    Vaccine; 2021 Nov; 39(46):6787-6795. PubMed ID: 34656378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines.
    Wysocki J; Tansey S; Brachet E; Baker S; Gruber W; Giardina P; Arora A
    Vaccine; 2010 Nov; 28(49):7779-86. PubMed ID: 20883736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany.
    Kieninger DM; Kueper K; Steul K; Juergens C; Ahlers N; Baker S; Jansen KU; Devlin C; Gruber WC; Emini EA; Scott DA;
    Vaccine; 2010 Jun; 28(25):4192-203. PubMed ID: 20417262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR
    Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM(197) protein conjugate; Prevenar ) in Korean infants: differences that are found in Asian children.
    Kim NH; Lee J; Lee SJ; Lee H; Kim KH; Park SE; Lee HJ
    Vaccine; 2007 Nov; 25(45):7858-65. PubMed ID: 17931753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.
    Juergens C; Trammel J; Shoji Y; Patterson S; Watson W; Webber C; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2018; 14(8):1948-1956. PubMed ID: 29543583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children.
    Tseng HF; Sy LS; Liu IL; Qian L; Marcy SM; Weintraub E; Yih K; Baxter R; Glanz JM; Donahue J; Naleway A; Nordin J; Jacobsen SJ
    Vaccine; 2013 May; 31(22):2578-83. PubMed ID: 23579258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.
    Plosker GL
    Paediatr Drugs; 2013 Oct; 15(5):403-23. PubMed ID: 24030738
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.